EDS-FLU improved symptoms, sinus opacification, acute exacerbations in two randomized trials in adults with chronic rhinosinusitis<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Jan. 26, 2024 (HealthDay News) — For patients with chronic rhinosinusitis (CRS), an exhalation delivery system that delivers fluticasone (EDS-FLU) to sinonasal areas above the inferior turbinate is efficacious, irrespective of nasal polyps, according to a study published online Jan. 18 in the Journal of Allergy and Clinical Immunology: In Practice<\/em>.<\/p>\n James N. Palmer, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined EDS-FLU efficacy for CRS in two randomized, EDS-placebo-controlled trials in adults with CRS irrespective of polyps (ReOpen1; 332 patients) or exclusively without polyps (ReOpen2; 223 patients). For 24 weeks, patients received EDS-FLU one or two sprays\/nostril or EDS-placebo twice daily.<\/p>\n The researchers found that the composite symptom score least-squares mean change for EDS-FLU one or two sprays\/nostril versus EDS-placebo was \u00e2\u0088\u00921.58 and \u00e2\u0088\u00921.60 versus \u00e2\u0088\u00920.62 in ReOpen1, and \u00e2\u0088\u00921.54 and \u00e2\u0088\u00921.74 versus \u00e2\u0088\u00920.81 in ReOpen2. Sinus opacification least-squares mean change for one or two sprays\/nostril of EDS-FLU versus EDS-placebo was \u00e2\u0088\u00925.58 and \u00e2\u0088\u00926.20 versus \u00e2\u0088\u00921.60 in ReOpen1 and \u00e2\u0088\u00927.00 and \u00e2\u0088\u00925.14 versus +1.19 in ReOpen2. Compared with EDS-placebo, acute disease exacerbations were reduced by 56 to 66 percent with EDS-FLU. For patients using standard-delivery nasal steroid products just before entering the study, there were significant symptom reductions of a similar magnitude observed. Similar adverse events were seen to those with standard-delivery intranasal steroids.<\/p>\n “These findings provide strong evidence for an effective, noninvasive treatment option for people who continue to experience symptoms after over-the-counter medications have failed,” Palmer said in a statement.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including OptiNose US, which funded the study.<\/p>\n